Positive outcome of average volume-assured pressure support mode of a Respironics V60 Ventilator in acute exacerbation of chronic obstructive pulmonary disease: a case report by Miyuki Okuda et al.
JOURNAL OF MEDICAL
CASE REPORTS
Okuda et al. Journal of Medical Case Reports 2012, 6:284
http://www.jmedicalcasereports.com/content/6/1/284CASE REPORT Open AccessPositive outcome of average volume-assured
pressure support mode of a Respironics V60
Ventilator in acute exacerbation of chronic
obstructive pulmonary disease: a case report
Miyuki Okuda1*, Makoto Kashio1, Nobuya Tanaka1, Takashi Fujii1 and Yoshinari Okuda2Abstract
Introduction: We were able to treat a patient with acute exacerbation of chronic obstructive pulmonary disease
who also suffered from sleep-disordered breathing by using the average volume-assured pressure support mode of
a Respironics V60 Ventilator (Philips Respironics: United States). This allows a target tidal volume to be set based on
automatic changes in inspiratory positive airway pressure. This removed the need to change the noninvasive
positive pressure ventilation settings during the day and during sleep. The Respironics V60 Ventilator, in the average
volume-assured pressure support mode, was attached to our patient and improved and stabilized his sleep-related
hypoventilation by automatically adjusting force to within an acceptable range.
Case presentation: Our patient was a 74-year-old Japanese man who was hospitalized for treatment due to
worsening of dyspnea and hypoxemia. He was diagnosed with acute exacerbation of chronic obstructive
pulmonary disease and full-time biphasic positive airway pressure support ventilation was initiated. Our patient was
temporarily provided with portable noninvasive positive pressure ventilation at night-time following an
improvement in his condition, but his chronic obstructive pulmonary disease again worsened due to the
recurrence of a respiratory infection. During the initial exacerbation, his tidal volume was significantly lower during
sleep (378.9 ± 72.9mL) than while awake (446.5 ± 63.3mL). A ventilator that allows ventilation to be maintained by
automatically adjusting the inspiratory force to within an acceptable range was attached in average volume-assured
pressure support mode, improving his sleep-related hypoventilation, which is often associated with the use of the
Respironics V60 Ventilator. Polysomnography performed while our patient was on noninvasive positive pressure
ventilation revealed obstructive sleep apnea syndrome (apnea-hypopnea index = 14), suggesting that his chronic
obstructive pulmonary disease was complicated by obstructive sleep apnea syndrome.
Conclusion: In cases such as this, in which patients with severe acute respiratory failure requiring full-time
noninvasive positive pressure ventilation therapy also show sleep-disordered breathing, different ventilator settings
must be used for waking and sleeping. On such occasions, the Respironics V60 Ventilator, which is equipped with
an average volume-assured pressure support mode, may be useful in improving gas exchange and may achieve
good patient compliance, because that mode allows ventilation to be maintained by automatically adjusting the
inspiratory force to within an acceptable range whenever ventilation falls below target levels.* Correspondence: ryoheikunn@msf.biglobe.ne.jp
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Full list of author information is available at the end of the article
© 2012 Okuda et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Okuda et al. Journal of Medical Case Reports 2012, 6:284 Page 2 of 5
http://www.jmedicalcasereports.com/content/6/1/284Introduction
The Respironics V60 Ventilator (Philips Respironics;
United States) debuted in Europe and United States of
America in 2009 and in Japan in 2010 as a successor
model to the Vision Ventilator in providing biphasic
positive airway pressure support ventilation (BiPAP)
(Figure 1).
Pressure-controlled ventilation and average volume-
assured pressure support (AVAPS) have been added as
new ventilation modes to this model. We were able to
treat a patient with acute exacerbation of chronic ob-
structive pulmonary disease (COPD), who also suffered
from sleep-disordered breathing (SDB), without having
to change the noninvasive positive pressure ventilation
(NPPV) settings during the day and during sleep by
using the AVAPS mode, which allows a target tidal vol-
ume to be set based on automatic changes in inspiratory
positive airway pressure (IPAP).
Case presentation
A 74-year-old Japanese man was being treated at home
for type II respiratory failure due to COPD, but at the
end of July 2011 he developed a fever of around 38°C
and his dyspnea worsened. The oxygen flow rate was
increased, but his hypoxemia failed to improve, and
acute exacerbation of COPD was diagnosed on examin-
ation by his primary care physician. He was referred to
our hospital and was hospitalized for further testing and
treatment.Figure 1 The Respironics V60 Ventilator.Our patient was 160cm tall, weighed 40kg, and had a
temperature of 37.6°C. His heart rate was normal, at 110
beats/min, with an elevated respiratory rate of 28
breaths/min, blood pressure of 116/77mmHg, and oxy-
gen saturation (SpO2) of 97% on nasal oxygen at 3L/min.
Chest auscultation revealed bronchial rales in both his
lower pulmonary fields. His white blood cell count was
within the normal range, but his levels of C-reactive
protein were highly elevated. Blood gas testing revealed
pronounced hypercapnia (pH 7.292, partial pressure of
oxygen (PaO2) 118.8mmHg, partial pressure of carbon
dioxide (PaCO2) 81.5mmHg, bicarbonate (HCO3
-)
38.2mmol/L, O2 intake 3L/min).
Radiography showed bilateral emphysematous lesions
across all his pulmonary fields, with left diaphragmatic
elevation and a right mediastinal shift (Figure 2).
Chest radiography and computed tomography showed
no evidence of pneumonia, and he was diagnosed with
acute exacerbation of COPD due to a respiratory tract
infection on the basis of his clinical symptoms and
sputum test results. He was placed on 24-h NPPV
using a BiPapW VisionW Ventilatory Support System
(IPAP, 8cmH2O; expiratory positive airway pressure
(EPAP), 4cmH2O; spontaneous-timed (ST) mode), and
was started on an antibiotic and a diuretic. As his re-
spiratory status stabilized, he was taken off NPPV,Figure 2 Chest roentgenography on admission showing
multiple bullae and bilateral emphysema with left
diaphragmatic hernia.
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his physical findings temporarily resolved. From
around hospital day 32, however, a respiratory tract
infection that may have been caused by aspiration
triggered another episode of acute COPD exacerba-
tion, with a depressed level of consciousness. This
time, NPPV management was implemented using a
Respironics V60 Ventilator (recently introduced at our
institution) in AVAPS mode (IPAP, 8 to 10cmH2O;
EPAP, 4cmH2O; target tidal volume, 350mL). Initial
findings of pH 7.189, PaCO2 136mmHg, PaO2
108.1mmHg and HCO3
- 50.0mmol/L were indicative of
hypercapnia and acidosis, and improved markedly to
pH 7.508, PaCO2 251.1mmHg, and PaO2 75.9mmHg
after one day on the V60 ventilator. NPPV was con-
ducted using two different ventilators for his two epi-
sodes of acute COPD exacerbation. During BiPAP, his
tidal volume was significantly decreased during sleep
compared with waking hours, but use of the AVAPS
mode of the Respironics V60 Ventilator automatically
corrected the IPAP and was able to improve his
sleep-related alveolar hypoventilation (Figure 3 and
Additional file 1: Table S1). A polysomnography (PSG)
was performed to diagnose our patient’s sleep respira-
tory disorder after his second episode of acute
exacerbation.
The results of the PSG were as follows: sleep effi-
ciency, 75.5%; apnea-hypopnea index, 14.0/h; apnea
index, 2.7/h; hypopnea index, 11.3/h; mean nocturnal
SpO2, 94%; minimum SpO2, 87%; SpO2<90% time (min)
15.0% with NPPV (ST with IPAP, 8cmH2O; EPAP,
4cmH2O; respiratory rate, 14/min; O2, 1.5L/min).Tidal volume (ml) 
Figure 3 Standard deviation indicating variance in tidal volume
during spontaneous-timed and average volume-assured
pressure support therapy. ST: spontaneous/timed mode, AVAPS:
average volume-assured pressure support, SD: spontaneous/timed
mode.Discussion
Various lines of evidence have confirmed NPPV as useful
for treating acute exacerbation of COPD [1-3]. The Global
Initiative for Chronic Obstructive Lung Disease also
recommends NPPV as the best option for effectively redu-
cing the need for intubation, reducing nosocomial infec-
tions, primarily pneumonia associated with intubated
mechanical ventilation, and reducing mortality [4]. The
BiPapW VisionW Ventilatory Support System, which is gen-
erally used as an NPPV-dedicated device, was also used for
the first episode of acute exacerbation in this case, and was
able to improve the serious deterioration in respiratory sta-
tus caused by the acute COPD exacerbation without intu-
bated mechanical ventilation. According to the respiratory
management records at that time, a significant decrease in
his tidal volume was seen while our patient was asleep
(378.9 ± 72.9mL) compared with his daytime tidal vol-
ume (446.5 ± 63.3mL) (Figure 3). The AVAPS mode of
the Respironics V60 Ventilator was therefore used in an
attempt to improve sleep-related hypoventilation during
his second episode of acute COPD exacerbation. The
Respironics V60 Ventilator, a successor model to the
BiPapW VisionW Ventilatory Support System, comes with
more sophisticated monitoring, an Auto-Trak™ system,
and C-Flex™, as well as the addition of pressure-
controlled ventilation and AVAPS ventilation modes.
AVAPS is a new ventilation mode for pressure-support
ventilation. The acceptable inspiratory range (IPAP(Max),
IPAP(Min)) and target ventilation (Target VTE) are set,
and respiration is monitored during ventilation, thereby
allowing the ventilation to be maintained through auto-
matic adjustment of the inspiratory force to within an ac-
ceptable range whenever the ventilation falls below the
target level. Use of AVAPS has already been reported to
have improved pronounced sleep-related decreases in
oxygen saturation in a patient with congenital central
hypoventilation syndrome [5]. This mode offers a greater
improvement in ventilation efficiency during sleep, as
compared with BiPAP, in patients with obesity
hypoventilation syndrome resulting in significantly lower
transcutaneous carbon dioxide [6]. A report of a rando-
mized trial on the relationship between AVAPS and pres-
sure support and improved sleep quality in nine patients
with stable chronic hyperapnic COPD [7] concluded that,
despite the short five-day period of use in the two modes
in the study, AVAPS was as comfortable and effective as
pressure support in alleviating respiratory acidosis, and
produced better sleep efficiency than pressure support.
We therefore used the V60 Ventilator in AVAPS mode in
our patient, who exhibited sleep-related hypoventilation
during the use of BiPAP. The ease with which IPAP set-
tings for target ventilation are changed in AVAPS mode
resulted in good patient compliance (his British Medical
Research Council scale decreased to four from five) and
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tings from a mean daytime IPAP of 9.2cmH2O to a noc-
turnal IPAP of 9.6cmH2O. In fact, no significant
difference was identified between daytime tidal volume
(440.8 ± 36.4mL) and nocturnal tidal volume (438.1 ±
52.4mL) when AVAPS was used (Figure 3).
Various mechanisms are thought to contribute to the
nocturnal hypoxemia that occurs with COPD [8]. First,
COPD patients are exposed to hypoxemia while awake.
Because this results in lower chemoresponsiveness of
the respiratory center, nocturnal hypoxia or hypercarbia
occur more readily. Second, muscular hypotonia of the
skeletal muscles, including the respiratory muscles,
occurs during sleep, particularly during rapid eye move-
ment (REM) sleep. Respiration in patients with COPD is
highly dependent on the accessory muscles of inspiration
as opposed to the diaphragm, and this hypotonia during
REM thus results in worsening of sleep-related alveolar
hypoventilation. This, combined with factors such as
decreased functional residual capacity, increases upper
airway resistance and exacerbates ventilation-perfusion
mismatch, resulting in profound hypoxemia, particularly
during REM sleep. The possibility of nocturnal hypoxia
in patients with COPD is therefore extremely important
and requires appropriate management of ventilation
during sleep. However, simply administering oxygen be-
cause of evidence of sleep hypoxia without taking
hypoventilation and obstructive sleep apnea syndrome
(OSAS) into consideration may lead to pronounced
hypercapnia. Flenley included patients with this COPD
(chronic bronchitis type) and sleep apnea syndrome
(SAS) in the overlap syndrome category [9]. COPD is
classified into the emphysema type (pink puffers) and
the chronic bronchitis type (blue bloaters). In the latter
patients in particular, advanced gas exchange disturb-
ance and upper airway obstruction are believed to result
in further exacerbation of hypoventilation during sleep
and a pronounced tendency toward serious respiratory
failure. A high percentage of patients with chronic bron-
chitis type are also thought to have OSAS, because such
patients are often obese. The patient in our case had a
very low body mass index of 15.6kg/m2 and was very
thin, yet the PSG while our patient was on NPPV
revealed SAS characterized by an apnea-hypopnea index
of 14.0/h. Hypopnea-induced SDB predominated, at
11.3/h. These results are consistent with the report that
the sleep hypoxia observed in patients with COPD is
caused by hypopnea, whereas apnea is seldom observed
[10]. OSAS is reportedly often more severe in Asians,
considering that their body mass index is generally lower
than in Westerners. This may be because of the more
pronounced association of upper airway obstruction
with smaller jaws and short necks [11]. The patient in
our case also had a left diaphragmatic hernia, which mayhave exacerbated respiratory function failure in the su-
pine position.
If measurement of nocturnal oxygen saturation reveals
decreased oxygen saturation in patients with COPD, par-
ticularly those who also have pulmonary hypertension,
PSG should be performed and appropriate treatment
should be started. Simple administration of oxygen for
sleep hypoxia can exacerbate hypercarbia at such times.
Therefore, when upper airway obstruction predominates,
some type of assisted ventilation will be needed for con-
tinuous positive airway pressure. In fact, in a study of
patients with overlap syndrome not treated with CPAP
(213 patients) compared with a group of patients with
COPD alone (210 patients), the untreated group was
associated with greater mortality (relative risk, 1.79; 95%
confidence interval, 1.16-2.77) and acute exacerbations
(relative risk, 1.70; 95% confidence interval, 1.21-2.38),
but CPAP treatment was associated with improved sur-
vival (overlap patients with CPAP compared with the un-
treated overlap group, 7.5% versus 14.5% mortality,
respectively) [12]. It has recently been recommended that
NPPV should be used proactively as first-line treatment
to improve not only acute exacerbations in patients with
chronic respiratory failure, but also pulmonary edema
due to acute cardiac failure [13]. European and Japanese
guidelines recommend keeping SpO2 at 95% to 98% or
more as a marker of oxygenation, but the large-scale
ADHERE clinical trial on heart failure, which has enrolled
more than 100,000 participants, revealed that as many as
approximately 40% of patients fail to achieve SpO2 ≥95%
[14]. Early introduction of NPPV is therefore a better option
when routine oxygen administration fails to improve oxy-
genation. Patients with chronic heart failure often have SDB
in the same manner as patients with chronic respiratory fail-
ure. Ferrier et al. reported that 53% of patients with heart
failure have OSAS and that 13% have central SAS [15]. It is
thus essential, in patients with heart failure as well, to be
mindful of the complication of SDB during acute exacerba-
tion and to set up a ventilator.
Conclusion
On such occasions, the Respironics V60 Ventilator,
which is equipped with an AVAPS mode, may be useful
in improving gas exchange and may achieve good pa-
tient compliance, because that mode allows ventilation
to be maintained by automatically adjusting inspiratory
force to within an acceptable range whenever ventilation
falls below target levels.
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